natgillin/translations-raw huggingface dataset:
Patients receiving pomalidomide either in combination with bortezomib and dexamethasone or in combination with dexamethasone have developed venous thromboembolic events (predominantly deep vein thrombosis and pulmonary embolism) and arterial thrombotic events (myocardial infarction and cerebrovascular accident).
Pri bolnikih, ki so prejemali pomalidomid bodisi v kombinaciji z bortezomibom in deksametazonom ali v kombinaciji z deksametazonom, so se razvili venski trombembolični dogodki (zlasti globoka venska tromboza in pljučna embolija) in arterijski trombotični dogodki (miokardni infarkt in cerebrovaskularni dogodek).
Not Known Hepatitis B reactivation
neznana pogostnost reaktivacija hepatitisa B
PFS was evaluated in several relevant subgroups: gender, race, ECOG performance status, stratification factors (age, disease population, prior anti-myeloma therapies [2, > 2]), selected parameters of prognostic significance (baseline beta-2 microglobulin level, baseline albumin levels, baseline renal impairment, and cytogenetic risk), and exposure and refractoriness to prior anti-myeloma therapies.
PFS je bilo ocenjeno v številnih pomembnih podskupinah: spol, rasa, status zmogljivosti po ECOG, stratifikacijski dejavniki (starost, populacija bolezni, predhodne terapije proti plazmocitomu [2, > 2]), izbrani parametri prognostične pomembnosti (raven beta-2 mikroglobulina ob izhodišču, ravni albumina ob izhodišču, okvara ledvic ob izhodišču in citogenetsko tveganje) in izpostavljenost in odpornost na predhodna zdravljenja proti plazmocitomu.
These cells grow out of control and accumulate in the bone marrow.
Te celice začnejo nenadzorovano rasti in se kopičiti v kostnem mozgu.
Hepatic impairment has a modest effect on the pharmacokinetics of pomalidomide (see section 5.2).
Okvara jeter zmerno vpliva na farmakokinetiko pomalidomida (glejte poglavje 5.2).
It is unknown whether pomalidomide is excreted in human milk.
Ni znano, ali se pomalidomid izloča v materino mleko.
You and your partner should use effective methods of contraception while taking this medicine.
Med jemanjem tega zdravila morate vi in vaš partner uporabljati zanesljivo metodo kontracepcije.
• Documentation of childbearing potential status
• dokumentacijo o statusu zmožnosti zanositve,
Therefore, erythropoietic agents, as well as other agents that may increase the risk of thromboembolic events, should be used with caution.
Zato je treba eritropoetska zdravila ali druga zdravila, ki lahko povečajo tveganje za trombozo, uporabljati previdno.
If you are uncertain whether any of the conditions above apply to you, talk to your doctor, pharmacist or nurse before taking Imnovid.
Če ste negotovi, ali kateri od zgornjih pogojev velja za vas, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden vzamete zdravilo Imnovid.
Haemorrhagic disorders have been reported with pomalidomide, especially in patients with risk factors such as concomitant medicinal products that increase susceptibility to bleeding.
Pri uporabi pomalidomida so poročali o krvavitvah, posebno pri bolnikih z dejavniki tveganja, kot so sočasna zdravila, ki zvečajo dovzetnost za krvavitve.
Kaplan-Meier Curve of Overall Survival (ITT Population)
Krivulja celokupnega preživetja po lestvici Kaplan-Meier (populacija ITT)
This condition is called tumour lysis syndrome.
To stanje se imenuje sindrom tumorske lize;
6.6 Special precautions for disposal and other handling Capsules should not be opened or crushed.
6.6 Posebni varnostni ukrepi za odstranjevanje Kapsul ne odpirajte in ne drobite.
Pomalidomide has a mean total body clearance (CL/F) of approximately 7-10 L/hr.
Pomalidomid ima povprečen skupni telesni očistek (CL/F) približno 7-10 l/uro.
Febrile neutropenia (FN) was reported in 3.2-6.7% of patients and was serious in 1.8-4.0% of patients (see section 4.2 and 4.4).
O febrilni nevtropeniji (FN) so poročali pri 3,2- 6,7 % bolnikov, resna je bila pri 1,8- 4,0 % bolnikov (glejte poglavji 4.2 in 4.4).
Your doctor should ask you to have a blood test:
Zdravnik bo opravil krvno preiskavo:
Cardiac events, including congestive cardiac failure, pulmonary oedema and atrial fibrillation (see section 4.8), have been reported, mainly in patients with pre-existing cardiac disease or cardiac risk factors.
Poročali so o dogodkih, povezanih s srcem, vključno s kongestivnim popuščanjem srca, pljučnim edemom in atrijsko fibrilacijo (glejte poglavje 4.8), predvsem pri bolnikih s predhodnimi boleznimi srca ali dejavniki tveganja za srce.
• Patient confirmation form ensuring that patients receive the appropriate counselling concerning the treatment, contraceptive methods and pregnancy prevention appropriate for their sex and childbearing status
• obrazec potrditve bolnika, ki zagotavlja, da so bili bolniki deležni ustreznega svetovanja o zdravljenju, kontracepcijskih metodah in preprečevanju nosečnosti, ki ustreza spolu in statusu zmožnosti zanositve,
For information on other medicinal products given in combination with Imnovid, refer to the respective current SmPC.
Za informacije o drugih zdravilih, ki jih dajete v kombinaciji z zdravilom Imnovid, glejte zadevni veljavni SmPC.
Adverse reactions tended to occur more frequently within the first 2 cycles of treatment with pomalidomide.
Neželeni učinki so bili pogostejši v prvih 2 ciklih zdravljenja s pomalidomidom.
• She understands the need and accepts to undergo pregnancy testing at least every 4 weeks except in case of confirmed tubal sterilisation
• mora razumeti potrebo in biti pripravljena opraviti teste nosečnosti vsaj vsake 4 tedne, razen v primeru potrjene sterilizacije jajcevodov,
• He understands the expected teratogenic risk if engaged in sexual activity with a pregnant woman or a woman of childbearing potential
• mora razumeti pričakovano tveganje za teratogene učinke, če spolno občuje z nosečnico ali žensko v rodni dobi;
4.5 Interaction with other medicinal products and other forms of interaction Effect of pomalidomide on other medicinal products
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Imnovid is either used with:
Zdravilo Imnovid se uporablja bodisi z:
As a precaution, all male patients taking pomalidomide should use condoms throughout treatment duration, during dose interruption and for 7 days after cessation of treatment if their partner is pregnant or of childbearing potential and has no contraception (see sections 4.3 and 4.4).
Zato morajo zaradi previdnosti vsi moški, ki se zdravijo s pomalidomidom, med zdravljenjem, prekinitvami odmerjanja in 7 dni po koncu zdravljenja uporabljati kondome, če je njihova partnerica v rodni dobi, in če ne uporablja zanesljive kontracepcije (glejte poglavje 4.3 in 4.4).
In clinical studies, no dose adjustment was required in elderly (> 65 years) patients exposed to pomalidomide (see section 4.2).
V kliničnih študijah pri starejših bolnikih (> 65 let), izpostavljenih pomalidomidu, prilagoditev odmerka ni bila potrebna (glejte poglavje 4.2).
Dispensing of pomalidomide to women of childbearing potential should occur within 7 days of the prescription and following a medically supervised negative pregnancy test result.
Ženski v rodni dobi je dovoljeno pomalidomid izdati v roku 7 dni od izdaje recepta in zdravstveno nadzorovanega negativnega rezultata testa nosečnosti.
Based on population pharmacokinetic analyses in healthy subjects and multiple myeloma patients, no significant influence of age (19-83 years) on oral clearance of pomalidomide was observed.
Na podlagi analiz populacijske farmakokinetike pri zdravih preskušancih in bolnikih z diseminiranim plazmocitomom niso ugotovili pomembnega vpliva starosti (19-83 let) na peroralni očistek pomalidomida.
Repeat-dose toxicology studies
Toksikološke študije pri ponavljajočem odmerku
Pomalidomide should be interrupted pending investigation of these symptoms and if ILD is confirmed, appropriate treatment should be initiated.
Do zaključka preiskave teh simptomov je treba zdravljenje s pomalidomidom prekiniti in, če je IPB potrjena, uvesti ustrezno zdravljenje.
The p-value is based on a stratified log-rank test.
Vrednost p temelji na stratificiranem testu log-rank.
In the 9-month study in monkeys with doses of 0.05, 0.1, and 1 mg/kg/day, morbidity and early euthanasia of 6 animals were observed at the dose of 1 mg/kg/day and were attributed to immunosuppressive effects (staphylococcal infection, decreased peripheral blood lymphocytes, chronic inflammation of the large intestine, histologic lymphoid depletion, and hypocellularity of bone marrow) at high exposures of pomalidomide (15-fold exposure ratio relative to a 4 mg clinical dose).
V 9-mesečni študiji pri opicah z odmerki 0,05, 0,1 in 1 mg/kg/dan so opazili obolevnost in zgodnjo evtanazijo 6 živali pri odmerku 1 mg/kg/dan, kar so pripisali imunosupresivnim učinkom (stafilokokne okužbe, znižanje limfocitov v periferni krvi, kronično vnetje debelega črevesa, histološko limfoidno izčrpavanje in hipocelularnost kostnega mozga) pri visoki izpostavljenosti pomalidomidu (15-kratnik izpostavljenosti glede na 4 mg klinični odmerek).
The primary efficacy endpoint was progression free survival by International Myeloma Working Group (IMWG criteria).
Primarni cilj študije za dokaz učinkovitosti je bilo preživetje brez napredovanja po kriterijih Mednarodne delovne skupine za plazmocitom (IMWG - International Myeloma Working Group).
• Obligations of the health care professional in relation to the prescribing of pomalidomide o Need to provide comprehensive advice and counselling to patients o That patients should be capable of complying with the requirements for the safe use of pomalidomide o Need to provide patients with appropriate patient educational brochure and patient card
• obveznosti, ki jih morajo zdravstveni delavci upoštevati pri predpisovanju pomalidomida: o potrebo po obsežnem posvetu in svetovanju bolnikom, o bolniki morajo biti sposobni upoštevati zahteve za varno uporabo pomalidomida, o bolnikom je treba izročiti ustrezno izobraževalno brošuro in kartico za bolnika;
Approximately 70% of patients were refractory to lenalidomide (71.2% in Pom+Btz+LD-Dex, 68.7 % in Btz+LD-Dex).
Približno 70 % bolnikov je bilo odpornih proti lenalidomidu (71,2 % v Pom+Btz+NO-deks, 68,7 % v Btz+NO-deks).
Peripheral neuropathy occurred in 55.4 % of patients (10.8% Grade 3; 0.7% Grade 4).
Periferna nevropatija se je pojavila pri 55,4 % bolnikov (pri 10,8 % 3. stopnje; pri 0,7 % 4. stopnje).
At the end of the treatment you should return all unused capsules to the pharmacist.
Na koncu zdravljenja morate vse neporabljene kapsule vrniti farmacevtu.
Direct Healthcare Professional Communications (Prior to Launch)
Ključni elementi, ki morajo biti vsebovani Neposredno obvestilo za zdravstvene delavce (pred prihodom zdravila na trg)
No data are available on administration of pomalidomide to paediatric patients (< 18 years of age).
Podatki o dajanju pomalidomida pediatričnim bolnikom (< 18 let starosti) niso na voljo.
As a result of these tests, your doctor may change your dose of Imnovid or stop your treatment.
Zdravnik lahko na podlagi rezultatov preiskav spremeni vaš odmerek zdravila Imnovid ali prekine zdravljenje.
• Brochure for women patients of childbearing potential and their partners
• brošure za ženske v rodni dobi in njihove partnerje,
Stop taking Imnovid and see a doctor straight away if you notice any of the following serious side effects - you may need urgent medical treatment:
Takoj prenehajte jemati zdravilo Imnovid in pojdite takoj k zdravniku, če opazite katerega od naslednjih neželenih učinkov - morda potrebujete nujno zdravniško pomoč:
All Adverse Reactions /Frequency
Vsi neželeni učinki /pogostnost
In the Btz+LD-Dex arm, median PFS time was 7.1 months (95% CI: 5.88, 8.48).
V skupini Btz+NO-deks je bil mediani čas PFS 7,1 meseca (95 % IZ: 5,88; 8,48).
If pomalidomide is taken during pregnancy, a teratogenic effect of pomalidomide in humans is expected (see section 4.4).
Pri jemanju pomalidomida med nosečnostjo se pri ljudeh pričakuje teratogeni učinek (glejte poglavje 4.4).
Dexamethasone should be discontinued if the patient is unable to tolerate 10 mg if ≤ 75 years old or 8 mg if > 75 years old.
Deksametazon je treba ukiniti, če bolnik ne more prenašati odmerka 10 mg pri starosti ≤ 75 let ali 8 mg pri starosti > 75 let.
Thrombocytopenia was Grade 3 or 4 in 20.7-27.3% of patients, led to pomalidomide discontinuation in 0.7% of patients and was serious in 0.4-1.7% of patients (see sections 4.2 and 4.4).
Trombocitopenija je bila 3. ali 4. stopnje pri 20,7-27,3 % bolnikov, povzročila je ukinitev pomalidomida pri 0,7 % bolnikov in je bila resna pri 0,4-1,7 % bolnikov (glejte poglavji 4.2 in 4.4).
• If your partner becomes pregnant while you are taking Imnovid, tell your doctor straight away.
• Če vaša partnerica zanosi, medtem ko jemljete zdravilo Imnovid, to takoj povejte zdravniku.
Interrupt pomalidomide treatment.
Prekinite zdravljenje s pomalidomidom.
• To conduct a non-interventional post-authorisation registry of patients treated with pomalidomide for relapsed and refractory multiple myeloma to monitor the incidence of adverse drug reactions in the “real world situation” and to monitor the implementation and compliance of the Celgene PPP and controlled distribution system on a country basis in agreement with the relevant National Competent Authority (ie., monitoring of Patient Card completion).
• Voditi neintervencijski register bolnikov, zdravljenih s pomalidomidom zaradi recidivnega in refraktarnega diseminiranega plazmocitoma, po pridobitvi dovoljenja za promet, za spremljanje incidence neželenih učinkov zdravila v "resničnih situacijah" in za spremljanje izvajanja programa preprečevanja nosečnosti družbe Celgene, ter nadzorovanega sistema distribucije v posameznih državah, v dogovoru z ustreznim pristojnim nacionalnim organom (tj. spremljanje izpolnitve bolnikove kartice).
Pomalidomide is extensively metabolised prior to excretion, with the resulting metabolites eliminated primarily in the urine.
Pomalidomid se pred izločanjem izčrpno presnovi, presnovki pa se izločijo pretežno v urinu.
Survival Time (weeks)
Čas preživetja (tedni)
Peripheral neuropathy occurred in 12.3% of patients (1.0% Grade 3 or 4).
Periferna nevropatija se je pojavila pri 12,3 % bolnikov (pri 1,0 % 3. ali 4. stopnje).
For patients > 75 years of age, the starting dose of dexamethasone is:
Za bolnike, stare > 75 let, je začetni odmerek deksametazona:
Pomalidomide is not anticipated to cause clinically relevant pharmacokinetic drug-drug interactions due to P450 isoenzyme inhibition or induction or transporter inhibition when co-administered with substrates of these enzymes or transporters.
Ne pričakuje se, da bi pomalidomid povzročil klinično pomembno farmakokinetično medsebojno delovanje zdravil zaradi zaviranja ali spodbujanja izoencima P450 ali zaviranja prenašalcev, če se uporablja sočasno s substrati teh encimov ali prenašalcev.
Patients with a history of severe rash associated with lenalidomide or thalidomide should not receive pomalidomide (see section 4.4).
Bolniki z anamnezo hudega izpuščaja, ki je bil povezan z zdravljenjem z lenalidomidom ali s talidomidom, ne smejo prejemati pomalidomida (glejte poglavje 4.4).
• A fall in the number of red and white blood cells and platelets at the same time (pancytopenia), which will make you more prone to bleeding and bruising.
• hkratno zmanjšanje števila rdečih in belih krvnih celic in trombocitov (pancitopenija), zaradi katere boste bolj nagnjeni h krvavitvam in podplutbam.
Dexamethasone should be discontinued if the patient is unable to tolerate 8 mg if ≤ 75 years old or 4 mg if > 75 years old.
Deksametazon je treba ukiniti, če bolnik ne more prenašati odmerka 8 mg pri starosti ≤ 75 let ali 4 mg pri starosti > 75 let.
• Description of the PPP and categorisation of patients based on sex and childbearing potential o Algorithm for implementation of PPP o Definition of women of childbearing potential (WCBP) and actions the physician should take if unsure
• opis PPN in razvrstitev bolnikov po spolu in zmožnosti zanositve: o algoritem za izvajanje PPN, o opredelitev žensk v rodni dobi (ŽRD) in ukrepov, ki jih mora zdravnik izvajati v primeru negotovosti.
• Pomalidomide in combination with bortezomib and dexamethasone In randomised study CC-4047-MM-007, 278 patients received pomalidomide, bortezomib and dexamethasone (Pom+Btz+Dex arm).
• Pomalidomid v kombinaciji z bortezomibom in deksametazonom V randomizirani študiji CC-4047-MM-007 je 278 bolnikov prejemalo pomalidomid, bortezomib in deksametazon (skupina s Pom+Btz+deks).
Do not use Imnovid if you notice any damage or signs of tampering to medicine packaging.
Ne uporabljajte zdravila Imnovid, če opazite, da je bila ovojnina poškodovana ali kaže znake zlorabe.
The Educational Healthcare Professional's Kit
Paket izobraževalnih gradiv za zdravstvene delavce
In rabbits, pomalidomide at dosages ranging from 10 to 250 mg/kg produced embryo-foetal developmental malforma tions.
Pri kuncih so razponi odmerka pomalidomida od 10 do 250 mg/kg povzročili embriofetalne razvojne deformacije.
Very Common Pneumonia (bacterial, viral and fungal infections, including opportunistic infections)
Infekcijske in parazitske bolezni zelo pogosti pljučnica (bakterijske, virusne in glivične okužbe, vključno z oportunističnimi okužbami)
Imnovid is expected to cause severe birth defects and may lead to the death of an unborn baby.
Pričakuje se, da bo zdravilo Imnovid povzročilo hude okvare pri nerojenem otroku in bi lahko povzročilo njegovo smrt.
• Dizziness, tremor.
• omotica, tresenje,
• Decreased ability to move or feel (sensation) in your hands, arms, feet and legs because of nerve damage (peripheral sensorimotor neuropathy).
• zmanjšana zmožnost gibanja ali občutkov (senzacij) v dlaneh, zgornjih udih, stopalih in spodnjih udih zaradi okvar živcev (periferna senzorimotorična nevropatija),
Pomalidomide must be discontinued permanently for angioedema.
Pri angioedemu je treba zdravljenje s pomalidomidom trajno ukiniti.
At 250 mg/kg/day, fetal malformations included limb anomalies (flexed and/or rotated fore- and/or hindlimbs, unattached or absent digit) and associated skeletal malformations (not ossified metacarpal, misaligned phalanx and metacarpal, absent digit, not ossified phalanx, and short not ossified or bent tibia); moderate dilation of the lateral ventricle in the brain; abnormal placement of the right subclavian artery; absent intermediate lobe in the lungs; low-set kidney; altered liver morphology; incompletely or not ossified pelvis; an increased average for supernumerary thoracic ribs and a reduced average for ossified tarsals.
Pri odmerku 250 mg/kg/dan so deformacije zarodka vključevale anomalije udov (zviti in/ali obrnjeni sprednji in/ali zadnji udi, nepritrjeni ali odsotni prsti) in povezane deformacije okostja (neokostenela dlančnica, neporavnani prstnica in dlančnica, odsotni prsti, neokostenela prstnica in kratka, neokostenela ali zvita golenica); zmerna razširitev lateralnega možganskega ventrikla; nenormalen položaj desne subklavijske arterije; odsoten vmesni pljučni lobus; nizka lega ledvic; spremenjena oblika jeter; nepopolna ali neokostenela medenica; zvišano povprečje odvečnih torakalnih reber in zmanjšano povprečje okostenelih nartov.
• That pomalidomide may cause thrombocytopenia and the need for regular blood tests
• da pomalidomid lahko povzroča trombocitopenijo; potrebne so redne krvne preiskave;
The pharmacokinetic parameters were modestly changed in hepatically impaired patients (defined by Child-Pugh criteria) compared to healthy subjects.
Farmakokinetični parametri pri bolnikih z okvaro jeter (opredeljeno po Child-Pughovih kriterijih) so bili v primerjavi z zdravimi osebami nekoliko spremenjeni.
Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking pomalidomide and dexamethasone, combined oral contraceptive pills are not recommended (see also section 4.5).
Zaradi povečanega tveganja za vensko trombembolijo pri bolnicah z diseminiranim plazmocitomom, ki jemljejo pomalidomid in deksametazon, uporaba kombiniranih peroralnih kontracepcijskih tablet ni priporočena (glejte tudi poglavje 4.5).
The most commonly reported serious adverse reaction was pneumonia (11.5%).
Resni neželeni učinek, o katerem so poročali najpogosteje, je bila pljučnica (11,5 %).
The mean increases in exposure to pomalidomide in each of these impairment groups are not of a magnitude for which adjustments in schedule or dose are required (see section 4.2).
Srednja zvečanja izpostavljenosti pomalidomidu v skupinah s temi okvarami niso bila tako velika, da bi bile potrebne prilagoditve sheme ali odmerka (glejte poglavje 4.2).
At 100 and 250 mg/kg/day, there were slight increases in post-implantation loss and slight decreases in fetal body weights.
Pri odmerkih 100 in 250 mg/kg/dan so opazili rahlo zvišanje izgube po ugnezditvi in rahlo znižanje telesne mase zarodka.
Population pharmacokinetic analyses showed that the pomalidomide pharmacokinetic parameters were not remarkably affected in renally impaired patients (defined by creatinine clearance or estimated glomerular filtration rate [eGFR]) compared to patients with normal renal function (CrCl ≥60 mL/minute).
Populacijske farmakokinetične analize so pokazale, da pri bolnikih z okvaro ledvic (opredeljeno z očistkom kreatinina ali ocenjeno hitrostjo glomerulne filtracije [eGFR - estimated glomerular filtration rate]) farmakokinetični parametri pomalidomida niso bili bistveno spremenjeni v primerjavi z bolniki z normalno funkcijo ledvic (CrCl ≥60 ml/minuto).
A medically supervised pregnancy test should be repeated at least every 4 weeks, including at least 4 weeks after the end of treatment, except in the case of confirmed tubal sterilisation.
Test nosečnosti pod zdravniškim nadzorom je treba ponoviti vsaj vsake 4 tedne, vključno z vsaj 4 tedne po koncu zdravljenja, razen v primeru potrjene sterilizacije jajcevodov.
Pomalidomide is structurally related to thalidomide.
Pomalidomid je strukturno soroden talidomidu.
• A core text as agreed by the CHMP.
• osrednjega besedila, kot ga je odobril Odbor za zdravila za uporabo v humani medicini (CHMP)
• Rapid breathing, rapid pulse, fever and chills, passing very little to no urine, nausea and vomiting, confusion, unconsciousness (due to infection of blood called sepsis or septic shock).
• pospešeno dihanje, pospešen srčni utrip, zvišana telesna temperatura in mrzlica, izločanje zelo malo ali nič urina, navzea in bruhanje, zmedenost, nezavest (zaradi okužbe krvi, ki se imenuje sepsa ali septični šok);
Neutropenia and thrombocytopenia tended to occur more frequently within the first 2 cycles of treatment with pomalidomide.
Nevtropenija in trombocitopenija sta kazali nagnjenje k pogostnejšemu pojavljanju v prvih 2 ciklih zdravljenja s pomalidomidom.
• Safety advice relevant to all patients o Description and management of thrombocytopenia including incidence rates from clinical studies o Description and management of cardiac failure o Disposal of unwanted medicine o Local country specific arrangements for a prescription for pomalidomide to be dispensed
• varnostne nasvete, primerne za vse bolnike: o opis ter obvladovanje trombocitopenije, vključno s stopnjo incidence v kliničnih študijah, o opis in obvladovanje srčnega popuščanja, o odstranjevanje odvečnega zdravila, o lokalne, za državo značilne dogovore glede predpisovanja in izdajanja pomalidomida.
Appropriate caution should be exercised when considering the treatment of such patients with pomalidomide.
Ko se ocenjuje možnost zdravljenja teh bolnikov s pomalidomidom je potrebna ustrezna previdnost.
If recovery from toxicities is prolonged beyond 14 days, then the dose of dexamethasone will be resumed at one dose level lower than the previous dose.
Če se okrevanje zaradi toksičnosti podaljša za več kot 14 dni, nadaljujte z odmerkom, za eno raven manjšim od predhodnega odmerka.
Stop using pomalidomide if you develop these symptoms and contact your doctor or seek medical attention immediately.
Če se vam pojavijo ti simptomi, prenehajte uporabljati pomalidomid in se takoj posvetujte z zdravnikom oziroma poiščite zdravniško pomoč.
• Imnovid and dexamethasone are taken in ‘treatment cycles'.
• Zdravilo Imnovid in deksametazon se jemljeta v ‘ciklih zdravljenja'.